Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.

Yun Dai, MD, PhD., Shuang Chen, MD, PhD, Xin-Yan Pei, MD, Viswanathan Ramakrishnan, Ph.D, Michael Wang, MD, MS., Robert Orlowski, PhD, Paul Dent, PhD, Steven Grant, MD

Blood (2009) 114 (22): 297.

https://doi.org/10.1182/blood.V114.22.297.297

Published: 2009

Journal Articles

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD, Sarah Kolla, Leonardo Andres Sirulnik, MD, PhD, Geoffrey Shapiro, Jeffrey Supko, Brenda Cooper, Edward Perkins, Viswanathan Ramakrishnan, Igor Espinoza-Delgado, MD, M B Tombes, John D Roberts

Blood (2008) 112 (11): 2986.

https://doi.org/10.1182/blood.V112.11.2986.2986

Published: 2008

Journal Articles

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Steven Grant, MD, Daniel Sullivan, David Roodman, MD, PhD, Robert K Stuart, MD, Edward Perkins, Sarah Kolla, Viswanathan Ramakrishnan, John Wright, MD, PhD, Alexander Dimitri Colevas, M B Tombes, John D Roberts

Blood (2008) 112 (11): 1573.

https://doi.org/10.1182/blood.V112.11.1573.1573

Published: 2008

Journal Articles

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Steven Grant, Daniel Sullivan, David Roodman, Robert Stuart, Edward B. Perkins, Viswanathan Ramakrishnan, John Wright, A. Dimitrios Colevas, John D. Roberts

Blood (2005) 106 (11): 3338.

https://doi.org/10.1182/blood.V106.11.3338.3338

Published: 2005

Journal Articles

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Steven Grant, Judith E. Karp, Omer N. Koc, Brenda Cooper, Selina Luger, William D. Figg, Merrill Egorin, Brian J. Druker, James W. Jacobberger, Viswanathan Ramakrishnan, Edward B. Perkins, A. Dimitrios Colevas, John D. Roberts

Blood (2005) 106 (11): 1102.

https://doi.org/10.1182/blood.V106.11.1102.1102

Published: 2005

NARROW

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only